Broad-based access to cost-effective, next-generation sequencing (NGS) and advances in synthetic biology have revolutionized the scale on which plasmids can be constructed, screened, and manipulated for wide-ranging applications, including biomarker discovery, antibody engineering, genome editing, and gene therapy. However, NGS library preparation throughput, performance, and cost remain bottlenecks in high-throughput plasmid sequencing.
Learn how seqWell’s multiplexed plexWell™ technology enables robust, high-throughput plasmid verification and screening in both research and commercial settings.
Read these blogs to find out how the plexWell™ technology enables Addgene to optimize the QC verification and validation of thousands of plasmids per year.
Download our Application Note to learn about our de novo plasmid assembly workflow, library preparation and sequencing data quality, and comparative performance vs. other plasmid sequencing workflows.
Frank A. Middleton, Ph.D.
Professor Director, SUNY Molecular Analysis CoreState University of New York (SUNY) Upstate Medical University
Joseph C. Mellor, Ph.D.
Co-founder and Chief Scientific Officer of seqWell Inc.